Who are Placebo Corifollitropin alfa's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Orgovyx, Orilissa, Firmagon, Luveris, Ovidrel, Cetrotide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-corifollitropin-alfa.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Placebo Corifollitropin alfa — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo Corifollitropin alfa (Placebo Corifollitropin alfa) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gonadotropin; long-acting FSH analog. Area: Reproductive/Fertility.

phase 3 Gonadotropin; long-acting FSH analog FSH receptor (FSHR) Reproductive/Fertility Small molecule Live · refreshed every 30 min

Target snapshot

Placebo Corifollitropin alfa (Placebo Corifollitropin alfa) — Organon and Co. Corifollitropin alfa is a long-acting follicle-stimulating hormone (FSH) analog that stimulates ovarian follicle development for assisted reproductive technology.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo Corifollitropin alfa TARGET	Placebo Corifollitropin alfa	Organon and Co	phase 3	Gonadotropin; long-acting FSH analog	FSH receptor (FSHR)
Orgovyx	relugolix	MYOVANT SCIENCES	marketed	Gonadotropin Releasing Hormone Receptor Antagonist [EPC]	Gonadotropin-releasing hormone receptor	2020-01-01
Orilissa	ELAGOLIX	AbbVie	marketed	Gonadotropin Releasing Hormone Receptor Antagonist	Gonadotropin-releasing hormone receptor	2018-01-01
Firmagon	degarelix	Ferring	marketed	Gonadotropin Releasing Hormone Receptor Antagonist	Gonadotropin-releasing hormone receptor	2008-01-01
Luveris	r-hLH	Merck KGaA	marketed	Gonadotropin	Lutropin-choriogonadotropic hormone receptor	2004-01-01
Ovidrel	CHORIOGONADOTROPIN ALFA	Merck KGaA	marketed	Gonadotropin	Lutropin-choriogonadotropic hormone receptor	2000-01-01
Cetrotide	CETRORELIX	Merck KGaA	marketed	Gonadotropin Releasing Hormone Receptor Antagonist	Gonadotropin-releasing hormone receptor	2000-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2036-02-25 — Orgovyx · 10350170 · US
2037-09-29 — Orgovyx · 10449191 · US
2037-09-29 — Orgovyx · 11583526 · US
2037-09-29 — Orgovyx · 11033551 · US
2037-09-29 — Orgovyx · 10786501 · US

Sponsor landscape (Gonadotropin; long-acting FSH analog class)

Organon and Co · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo Corifollitropin alfa — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-corifollitropin-alfa. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab